You just read:

Daratumumab Combination Therapy Improved Clinical Outcomes Regardless of Cytogenetic Risk for Previously-Treated Patients with Multiple Myeloma

News provided by

Janssen Research and Development LLC

Jun 04, 2017, 10:56 ET